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Abstract
Objective: The purpose of this study was to evaluate how poor retention in HIV care impacts time to viral suppression after
initiating highly active antiretroviral therapy. Methods: A retrospective cohort study design, employing a medical chart
review, was conducted at an academic infectious disease clinic at the University of Kentucky. Patients seeking care between
2003 and 2011 were included in the study. A log-normal model was employed to determine the factors associated with time
to viral suppression. Results: Of the 532 patients in the study, 426 (80.1%) patients were virally suppressed. Controlling for
insurance status, race, baseline CD4 counts, and viral loads, the expected time to viral suppression for nonoptimal retainers
was longer compared to optimal retainers (100% retained in care; time ratio: 2.04; 95% confidence interval: 1.40-2.90).
Conclusion: Researchers should continue to study the impact of retention on clinical outcomes and strategies to improve
retention and reengage those lost to follow-up back into care.
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Introduction
Once an individual has been diagnosed with HIV, early linkage to
and retention in continuous HIV medical care are arguably the 2
most important components to the continuum of HIV health care
which improve the health outcomes of individuals diagnosed and
living with HIV.1 It has been suggested that, in the United States
approximately 77% of the individuals diagnosed with HIV are
linked into care within 3 to 6 months after diagnosis, but only
51% of those that are linked actually remain in care.2 Maintaining
optimal retention in medical care is required among individuals
living with HIV to receive full access to all the treatment benefits.
Poor retention in care after initial linkage can be detrimental to an
individual’s health as this can delay the initiation of antiretroviral
therapy and can lead to more detrimental clinical events, such as
virological failure, AIDS, or death.3-7
With the major advancements in HIV medical care, HIV has
become a manageable chronic infectious disease. Initiating
highly active antiretroviral therapy (HAART) into the clinical
management of HIV has been shown to dramatically reduce the
morbidity and mortality due to HIV, including suppressing
viral loads (VL), which in turn reduces the risk of HIV transmission.8 Gardner et al1 suggested that approximately 25% of
the patients who are eligible to receive HAART are not receiving HAART due to refusal or failure to initiate therapy. Of
those who are receiving therapy, it is estimated that only
77% are virally suppressed. With approximately 23% of individuals estimated to be without a suppressed VL, it is believed that

barriers to achieving viral suppression among individuals who
have initiated HAART are poor medication adherence, nonpersistence, and resistance.1 Although this may be true, failure to
maintain optimal retention in HIV medical care may play a
significant role in the failure to achieve a suppressed VL.8
Poor retention in care represents an arduous obstacle to
achieving viral suppression, as this has important individual and
public health implications. Little research has been conducted on
the impact retention in care has on viral suppression, especially
after individuals initiate HAART.8-10 Understanding retention in
care and how it affects health outcomes among individuals initiating HAART for the first time is very important. Individuals
who have been linked to care and initiated HAART for the very
first time are at a vulnerable stage in the course of their infection,
as they are now expected to attend regularly scheduled clinic
visits and sustain near perfect levels of medication adherence,
and these individuals may not be prepared for the long-term
commitment that is attached to HIV care.
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The purpose of the study is to determine the impact retention
in care has on viral suppression after initiating HAART.
Employing parametric time to event methods, the hypothesis
is that poor retention in care after initiation of HAART will
delay time to viral suppression.

Methods
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information collected during the study included date of birth,
sex, race/ethnicity (white/nonwhite), marital status, employment
status, insurance status, poverty level (<100% below federal
poverty level), history of tobacco and illicit drug use (yes/no),
and transmission category (men who have sex with men [MSM],
heterosexual contact, injection drug users, and other). The clinical characteristics obtained included CD4 counts, VLs, history
of hepatitis C, date of HAART initiation, and date of death.

Study Design
A retrospective cohort study design, employing a medical chart
review, was conducted at the Bluegrass Care Clinic, an academic infectious disease clinic at the University of Kentucky,
to determine the impact retention in HIV medical care has on
time to viral suppression. Patients who sought care between
2003 and 2011, and had initiated HAART anytime during the
course of their infection, were considered eligible for this study
and were followed until December 31, 2011. In this study,
patients were followed from initiation of HAART until the
event of interest occurred (viral suppression) or until the end
of the study period (December 31, 2011), death, or movement
out of the service region. The study was approved by the
University of Kentucky Institutional Review Board.

Study Population and Eligibility
Data were abstracted from an electronic database. For the current study, patients who were seeking HIV medical care during
the study period were 18 years of age at the time of the study
and patients who had initiated HAART at any time during the
course of their infection were considered eligible for the study.
To be included in the current study, patients had to have at least
1 HIV outpatient medical clinic visit during the specified study
period (not including initiation of HAART), an initial VL
measurement with an actual date of result, a subsequent VL
measurement with an actual date attached, and a follow-up
greater than 6 months. Restricting the study to patients that
have a follow-up greater than 6 months allows time for patients
to obtain a subsequent VL measurement so that suppression can
be observed.
For the time to viral suppression study, patients that had a
VL measurement of <50 copies/mL at the time of the study
were excluded from the analysis. There were 1166 patients that
had initiated HAART and were eligible for the study, with 1108
(95%) having at least 1 VL recorded. Of the 1108 patients with
at least 1 VL recorded, only 973 (88%) patients had a VL with a
date recorded. For time to viral suppression, patients were
excluded from the analysis of the study if they had achieved
a suppressed VL (<50 copies/mL) prior to start of the study.
Of the 973 patients with a VL recorded during the study period,
532 (56%) had a VL that was >50 copies/mL at initiation of
HAART and were included for the analysis.

Study Measures
Demographic and clinical data were abstracted from the medical
records of the patients included in the study. Demographic

Retention in Care Measure
According to the current Department of Health and Human Services guidelines, newly diagnosed individuals should seek HIV
medical primary care at least every 3 to 4 months until their
immunological and virological response has been maintained
at the appropriate levels, and then once every 6 months after
that.11 Patients living with HIV who initiate HAART should
be monitored consistently, so that the patient can maintain
adherence and viral suppression. Retention in care was defined
as having at least 1 HIV medical outpatient clinic visit every 6
months. Patients were considered optimally retained in care if all
6-month patient care intervals had at least 1 clinic visit
completed.

Outcome Measures
The primary end point of the study was viral suppression and
was defined as having an HIV RNA level of <50 copies/mL.
Time to viral suppression (years) was defined as the time from
the initiation of HAART to the time of the first suppressed VL.

Statistical Analysis
Descriptive statistics were produced to describe the study
population by employing means, medians, standard deviations,
and ranges to describe all the continuous variables and frequencies and percentages to describe all the categorical variables.
Independent 2 sample t tests and Wilcoxon tests were used to
detect differences in continuous variables, while chi-square tests
were used to determine differences in categorical variables.
For the analysis of time to event data in most epidemiologic
studies, in particular HIV studies, the Cox proportional hazards
model has become the model of choice, but it has been argued
that parametric methods such as the accelerated failure time
(AFT) model may provide a more appropriate modeling framework.12,13 Advantages to employing parametric models are (1)
ability to use full maximum likelihood to estimate parameters;
(2) the estimated coefficients can provide estimates that may be
clinically meaningful; (3) estimates of survival time can be
provided from fitted values from the model; and (4) residuals
can be computed as differences between observed and predicted values of time.13,14 To determine the impact retention
has on time to viral suppression, AFT methods were employed.
In the time to event analysis for VL suppression, time was
measured from the start of HAART and analysis time ended
at the earliest date of a suppressed VL or at the end of the study
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Table 1. Association of Sociodemographic and Clinical Characteristics and Viral Suppression among the Patients Seeking HIV Medical Care and
Initiating HAART at the Bluegrass Care Clinic, 2003 to 2011.
Viral Suppression
Total n (%)
Total
Age at HAART, mean years (SD)
Sex—male
Race
Non-Hispanic white
Non-Hispanic black
Hispanic
Mode of transmission
MSM
Heterosexual
IDU
Other
Below poverty level
Illicit drug use—yes
Insurance type
None
Medicaid
Medicare
Private
AIDS diagnosis—yes
Hepatitis C—yes
CD4 count at baseline, median (min, max)
Viral load at baseline, mean log copies (SD)
Optimally retained—no

Yes, n (%)

No, n (%)

532 (100)
39.2 (9.35)
431 (81.0)

426 (80.1)
39.3 (9.45)
349 (81.9)

106 (19.9)
38.9 (8.96)
82 (77.4)

390 (73.3)
112 (21.1)
30 (5.6)

326 (76.5)
82 (19.3)
18 (4.2)

64 (60.4)
30 (28.3)
12 (11.3)

303 (57.0)
156 (29.3)
51 (9.6)
22 (4.1)
264 (49.6)
140 (26.3)

246 (57.8)
120 (28.2)
41 (9.6)
19 (4.5)
203 (47.7)
115 (27.0)

57
36
10
3
61
25

206 (39.2)
87 (16.4)
95 (17.9)
141 (26.6)
335 (62.9)
77 (14.5)
357.2 (1, 1690)
7.3 (3.2)
248 (46.6)

163 (38.4)
58 (13.7)
82 (19.3)
122 (28.7)
254 (59.6)
59 (13.9)
385.6 (1, 1690)
6.8 (3.12)
175 (41.1)

P Value
.68
.28
.001

.62
(53.8)
(34.0)
(9.4)
(2.8)
(57.6)
(23.6)

45 (42.5)
29 (27.4)
13 (12.3)
19 (17.9)
81 (76.4)
18 (17.0)
242.0 (2.0, 891.0)
9.1 (2.59)
73 (68.9)

<.0001
.48
.001

.001
.41
<.0001
<.0001
<.0001

Abbreviations: HAART, highly active antiretroviral therapy; IDU, injection drug user; MSM, men who have sex with men; SD, standard deviation.

period, death, or movement out of the service region. Those
individuals who did not achieve VL suppression or died were
right censored at the end of the study. Since the authors were
unaware of the exact date of viral suppression between VL dates,
interval censoring was also employed between the date of viral
suppression and the previous VL date. Kaplan-Meier estimates
were plotted overall and stratified by retention in care. Wilcoxon
tests were used to determine the differences in survival curves
between the retention groups and the other covariates.13,14
The primary objective was not to determine just the risk of
VL suppression but to determine how early retention impacted
time to VL suppression. Parametric survival models, in particular AFT models, were considered for the current analysis
because the acceleration factor allows us to evaluate the effect
of the predictor variables (retention) on the survival time as
opposed to the hazard like the proportional hazard models.13,14
Cox-Snell residual plots were produced to determine absolute
goodness of fit for the parametric model. For time to VL
suppression, the log-normal model was chosen. Variables with
a P value .15 in the univariate analysis were considered for
inclusion into the final model. To determine how retention in
care impacted time to viral suppression, the model controlled
for insurance status, race, CD4 counts at baseline, VL at baseline (log copies), income, history of AIDS, and year of HIV
diagnosis. Time ratios were the measures of association for this
analysis.

All data were analyzed using SAS version 9.3 (Cary, North
Carolina), and P values <.05 were regarded as statistically
significant.

Results
Demographic Characteristics
For the study sample (n ¼ 532), the mean age at the start of
HAART was 39.2 + 9.35 years. The majority of the patients
were men (81.0%) and white non-Hispanic (73.3%). The
majority of the patients’ reported mode of transmission was
MSM (57.0%), and 49.6% of the cohort were living below the
poverty level (Table 1).
At the start of the study, approximately 39.2% of the patients
did not have any form of insurance, with 34.3% having some
form of public assistance (Medicaid or Medicare). The median
CD4 count at initiation was 357.2 (1, 1690) cells/mm3, and the
mean log VL was 7.3 + 3.2 copies. At the end of the study
period, approximately 53% of the patients were optimally
retained in care (Table 1).
A total of 426 (80.1%) patients achieved a viral suppression
at least once during the study period. Those with a suppressed
VL were more likely to be white non-Hispanic (76.5% versus
60.4%, P ¼ .001) and those with private insurance (28.7% versus 17.9%, P ¼ .001). The patients with a suppressed VL were
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Table 2. Log-Normal Regression Determining the Association between Retention in HIV Medical Care and Time to Viral Suppression among
the Patients Seeking Care at the Bluegrass Care Clinic: 2003 to 2011.a

Variables
Retention (no versus yes)
Race (non-white versus white)
Insurance status
No insurance versus private
Medicaid versus private
Medicare versus private
Poverty level (above versus below)
AIDS diagnosis (no versus yes)
Baseline CD4 counts (per 100 cells/mm3)
Baseline viral load (per log copy/mL)

Unadjusted TR

95% CI

Adjusted TR

95% CI

2.72
1.51

1.83-4.06
0.96-2.37

2.04
1.47

1.40-2.90
0.98-2.19

1.16
2.84
1.34
0.69
0.41
0.92
1.00

0.69-1.94
1.50-5.40
0.72-2.52
0.44-1.08
0.27-0.64
0.84-1.01
0.93-1.08

1.44
2.06
1.01
1.03
0.59
0.95
1.07

0.86-2.40
1.08-3.95
0.57-1.77
0.65-1.62
0.37-0.94
0.86-1.04
1.00-1.14

Abbreviations: TR, time ratio; CI, confidence interval.
a
Bold numbers signify P values < .05.

less likely to be those living below the federal poverty level
(47.7% versus 57.6% P < .0001) and those on Medicaid
(13.7% versus 27.4%) and no insurance (38.4% versus
42.5%, P ¼ .001; Table 1).
Clinically, those with a suppressed VL were more likely to
have a higher median CD4 count (385.6 versus 242.0 cells/
mm3, P < .0001) and more likely to have a lower mean log VL
at initiation (6.8 versus 9.1 log copies, P < .0001). Viral suppression was also found to be less likely in those patients that were not
optimally retained in care throughout the study period (41.1%
versus 68.9%, P < .0001; Table 1).

compared to their counterparts (Table 2). Controlling for insurance status, race, baseline CD4 counts, and baseline VLs, the
expected time to viral suppression for nonoptimal retainers was
2.04 (95% confidence interval [CI]: 1.40-2.90) times greater
than those who were optimally retained in care. The expected
time to viral suppression for those Medicaid was 2.06 (95%
CI: 1.08-3.95) times greater compared to those with private
insurance, and those without an AIDS diagnosis had a shorter
time to viral suppression compared to those with an AIDS
diagnosis (time ratio ¼0.59; 95% CI: 0.37-0.94; Table 2).

Discussion
Time to Viral Suppression
Figure 1 presents the Kaplan-Meier curve for the 426 patients
that achieved a viral suppression, with those patients who did
not being right censored (n ¼ 106). The curve suggests a faster
progression within the first year of initiation to HAART,
followed by a much slower progression as the time increases.
The median time to viral suppression for the patients was
approximately 1.03 years. Figure 2 presents a Kaplan-Meier
curve of time to viral suppression stratified by retention in care.
The curve suggests that the patients who were optimally
retained in HIV medical care after the initiation of HAART had
a shorter time to viral suppression compared to those who were
not optimally retained in care. The median time to viral
suppression for optimal and nonoptimal retainers was 0.87 and
1.79 years, respectively (Wilcoxon test, P ¼ .002). The
estimated cumulative survival distribution for the log-normal
distribution was produced for optimal and nonoptimal retainers. The curves show results similar to the Kaplan-Meier
curves that optimal retainers have a higher chance of viral
suppression compared to the nonoptimal retainers (Figure 3).
In the log-normal models, the association with viral suppression was tested for all the variables in the univariate models,
and those with a P value <.15 in the unadjusted model were
included in the adjusted model. In the unadjusted log-normal
model, nonoptimal retainers, those on Medicaid, and those with
an AIDS diagnosis had longer times to viral suppression

The purpose of this study was to understand the effect retention
in care had on viral suppression among individuals receiving
HAART. There is a paucity of research on the examination of
the effect of retention in HIV medical care on time to viral suppression. For time to viral suppression, the authors selected a
small cohort of patients who were initiating HAART for the first
time and followed them from the time of HAART initiation to
the time of their first suppressed VL. Retention in care was
shown to be associated with time to viral suppression. Patients
that had optimal (100%) retention after initiating HAART were
more successful in achieving a suppressed VL, and the time it
took for suppression was much shorter than the patients who
were poorly retained in care. The results from this study are
consistent with those of Mugavero et al,8 which observed the
impact early retention (number of missed visits in the first year
of care) had on viral suppression, and they were able to show that
patients with perfect visit adherence were more likely to have a
viral suppression, and that each ‘‘no show’’ clinic visit conveyed
a 17% increased risk of delayed viral suppression.
The results of the current study convey important implications for individual patient outcomes as well as future public
health prevention efforts. Failure to achieve viral suppression
in a timely manner and maintain a suppressed VL can be damaging to the individual’s health; the longer it takes for an individual living with HIV to suppress their VL, the risk of detrimental
clinical events increases. Researchers have suggested that failure
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Figure 1. Kaplan-Meier curve of time to viral suppression among the patients initiating highly active antiretroviral therapy (HAART).

to suppress one’s VL can be an indicator of poor medication
adherence as well as medication resistance.1,5,15
From a public health standpoint, failure to achieve viral suppression can be damaging to prevention efforts, as patients with
high VLs may increase the risk of HIV transmission. In 2008,
Metsch et al16 conducted a study to show how recently diagnosed patients with optimal early retention in care had reductions in sexual risk behaviors compared to those who were
poorly retained. The authors were able to show that poor retention in HIV care, among individuals who had initiated HAART,
was a barrier for timely viral suppression, which in turn
impedes the potential reduction in transmission of HIV to others. This shows the importance of retention in care among individuals living with HIV and strategies should be developed to
help reengage those individuals who have fallen out of care as
this can improve their chances of viral suppression.
The patients in the study with Medicaid had challenges in
achieving timely viral suppression. Even when controlling for
the other variables in the parametric model, patients with
Medicaid had delays in viral suppression. The Medicaid
population has been consistently shown by researchers to be
poor retainers in care, poor viral suppressers, and viral rebounders.17-19 Studies should be conducted on this population to get
a better sense of why retention is poor, which can then lead to
poor HIV outcomes. Understanding the factors that prevent this
population from retaining in care and suppressing VLs can help

guide future prevention efforts to reengage this population back
into care.
This study was an observational, retrospective cohort study
and subject to potential uncontrolled confounders for which the
authors had no information, such as alcohol use and presence of
social and familial support networks. A medical chart review
was employed to capture patient’s data, and not all the patients
had complete information in their medical records. This was
the case for selecting patients for inclusion into the study who
had a VL and a follow-up measurement; 193 patients were
excluded from the analysis partly because they had missing
information regarding their HIV laboratory test results (eg,
VL recorded but no date or a VL date but no VL result). There
were no significant differences between those that were
excluded from the analysis in regard to demographic information, but exclusion of patients reduces the power of the study
and potentially introduces bias. Although the study clinic provides care for a large proportion of individuals diagnosed with
HIV who reside in central and eastern Kentucky, the results
may not be generalizable to all Kentuckians living with HIV
nor all individuals living with HIV in the United States. A
future research study conducted using similar methods should
involve a multicenter study across all Ryan White funded
clinics in Kentucky.
Another limitation to this study was the definition for retention. In the retention in care literature, it is debated as to what
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Figure 2. Kaplan-Meier curves of the time to viral suppression stratified by optimal retention.

Figure 3. Estimate cumulative incidence curves of time to viral suppression for the log-normal distribution.
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constitutes a clinic visit. For this study, retention was defined as
having at least 1 HIV medical primary care visit every 6
months. This limitation could lead to a misclassification bias,
as individuals who seek medical care from non-HIV providers
may be classified as poor retainers, therefore, overestimating
non-retainers in the study. There is a potential for selection and
misclassification bias, as individuals were removed from the
study when they did not have at least 6 months of follow-up.
Removing these individuals from the analysis may underestimate the number of poor retainers seeking medical care at the
Bluegrass Care Clinic. It was not feasible to find out whether
these individuals were seeking HIV medical care at other
clinics. The authors do not believe patients would seek care
at other clinics, often because most of the patients relied on
funding from the clinic for medication and patient care, and
other options for HIV/AIDS care in their region may be limited.
Finally, medication adherence was not observed or evaluated
for this study. Studies have observed the impact medication
adherence has on viral suppression and have suggested that
patients that are not at least 95% adherent to their medications
are more likely to have virological failures. Medication adherence is on the causal pathway between retention in care and
VL suppression, but the purpose of this study was to establish the
relationship between retention and VL suppression.20 It may be
concluded that medication adherence is the driving force behind
viral suppression, but Giordano et al5 were able to show that
poor retention in care and poor medication adherence were
highly correlated; therefore, it seemed appropriate to use retention in care as a surrogate measure. Also with this study, obtaining medication adherence was difficult as the patient population
at the clinic obtain their medications from multiple pharmacies,
which makes it difficult to track medication pick up once the
prescription has been written.

Conclusion
In conclusion, the authors were able to identify significant
associations between retention in care and viral suppression
among patients initiating HAART. Patients who were poorly
retained in care after initiating HAART prolonged their opportunity to achieve viral suppression compared to optimal retainers in care. The results of this study stress the importance of
maintaining optimal retention among individuals living with
HIV in order to increase the number of individuals with suppressed VLs. Researchers and clinicians should continue to
study the impact of retention in HIV medical care on clinical
outcomes and strategies to improve retention and reengage
those lost to follow-up back into care.
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